Press Releases

Cancer Diagnostics Market Size is Predicted to Hit US$ 258.54 Billion by 2030

The cancer diagnostics market size was USD 124.96 billion in 2021 and is expected to reach USD 258.54 billion by 2030. It is anticipated to grow with a healthy CAGR of 8.4% from 2021 to 2030.

In 2022, the cancer diagnostics market study provides crucial information on market share, market size, growth rate analysis Y-O-Y, production, consumption, and sales analysis for the forecast period 2021 to 2030. The report contains 150+ pages with detailed analysis.

Cancer is one of the leading causes of both illness and death around the world. In controlling these deaths, diagnosis of cancer at an early stage is equally important. At present, most of the death causing types of cancers is lungs, stomach, colorectal, liver, breast, and others. It is estimated that, more than 1.5 million individuals are losing their life in a year due to various kinds of cancer. The screening of the early symptoms is equally important. Technological advancement leads to new different methods for screening individuals. As per the professional, cancer-related death size can become down or the mortality rate can be reduced if the cases can be detected early and get treated on time. A cancer diagnosis can be performed by any one of the methods that depend upon the severity. These methods include a physical exam, laboratory test, biopsy, swab test, imaging test, and others.

Growth Factors

The mortality rate of cancer is comparatively higher than chronic related death. Many key strategies are applied by the governments around the world in order to control cancer. The various awareness programs run by government for controlling tobacco, maintaining physical activity, limit the use of alcohol, vaccination against the HPV, and hepatitis B. The awareness also includes the limited exposure of carcinogen, diet and stress-free related life, effective public health activities, and others. In addition, rising number of cancer patients followed by an increasing number of private diagnostic centers is also considered as one of the major factors for promoting the growth of the market.

Since past couple of years, developing countries like India, China, and Indonesia saw a marked growth in healthcare infrastructure development. This is considered as on one of the major driving factors which promote the growth of the market. However, lacs of diagnostic centers facilities and lack of diagnosis is also considered as one of the major restraining factors which affect the growth of the market.

Market Scope:

Report Highlights Details
Market Size US$ 258.54 Billion by 2030
Growth Rate CAGR of 8.4% From 2022 to 2030
Base Year 2021
Historic Data 2017 to 2021
Forecast Period 2022 to 2030
Segments Covered Test Type, Application
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

Regional Snapshots

In North America, cancer is the leading cause of death and at present, lung cancer is the leading cause of death in the U.S. In addition, breast cancer is frequently diagnosed in the North American region. National Cancer Institute stated that the burden of cancer increasing day by day in the U.S. Rising geriatric problem and modern lifestyle is one of the major causes for cancer related death. On the other hand, Europe is mostly affected by the geriatric population with a low birth rate. Countries like Germany, France, and UK population are highly diagnosed with cancer.

High population of China and India provide huge patient base which further promote the growth of the market in the Asia Pacific. The countries like Brazil in the Latin America holds more than the 60% market share of the cancer diagnostic market. The rise of patients in this region compared to the Asia Pacific and Latin America is due to the new screening test. Middle East is showing a substantial amount of treatment in the upcoming years. Thyroid cancer is common in females of Gulf Countries. As per the study, males are mostly suffering from lung cancer in the Gulf countries. However, lack of medical facilities in Africa affects the growth of cancer diagnostic market in this region.

COVID-19 Impact:

The industrial report mentions the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The cancer diagnostics report proficiently explains the resulting factors and concerns of manufacturers. Researchers have also well-explained how the producers and providers will tackle the ongoing epidemic and the key strategies to be adopted post-pandemic for turning their businesses back to normal.

Key Players:

The cancer diagnostics market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the prominent players in the cancer diagnostics market include:

  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Becton, Dickinson and Company
  • GE Healthcare
  • QIAGEN N.V.
  • Abbott Laboratories, Inc.
  • Roche Diagnostics
  • Siemens Healthcare
  • Philips Healthcare
  • R. Bard, Inc.
  • bioMérieux SA
  • NeoGenomics Laboratories, Inc.
  • Volpara Solutions Limited
  • Hologic Inc.
  • Canon Medical Systems Corporation
  • PenRad Technologies Inc.
  • BioNTech Diagnostics GmbH
  • BioGenex

Market Segmentation

By Product

  • Consumables
    • Antibodies
    • Kits & Reagents
    • Probes
    • Other Consumables
  • Instruments
    • Pathology-based Instruments
    • Slide Staining Systems
    • Tissue Processing Systems
    • Cell Processors
    • PCR Instruments
    • NGS Instruments
    • Microarrays
    • Other Pathology-based Instruments
  • Imaging Instruments
    • CT Systems
    • Ultrasound Systems
    • MRI Systems
    • Mammography Systems
    • Nuclear Imaging Systems
  • Biopsy Instruments

By Technology

  • IVD Testing
    • Polymerase Chain Reaction (PCR)
    • In Situ Hybridization (ISH)
    • Immunohistochemistry (IHC)
    • Next-generation Sequencing (NGS)
    • Microarrays
    • Flow Cytometry
    • Immunoassays
    • Other IVD Testing Technologies
  • Imaging
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET)
    • Mammography
    • Ultrasound
  • Biopsy Technique

By Application

  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

By End Use

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Research Institutes

Regional Segmentation

  • North America (U.S. and Canada)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Find More Press Releases at https://www.globenewswire.com/en/search/organization/Precedence%2520Research

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Diagnostics Market 

5.1. COVID-19 Landscape: Cancer Diagnostics Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Diagnostics Market, By Product

8.1. Cancer Diagnostics Market, by Product Type, 2022-2030

8.1.1. Consumables (Antibodies, Kits & Reagents, Probes, Other Consumables)

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Instruments (Pathology-based Instruments, Slide Staining Systems, Tissue Processing Systems, Cell Processors, Others)

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Imaging Instruments (CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Nuclear Imaging Systems)

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Biopsy Instruments

8.1.4.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Cancer Diagnostics Market, By Technology

9.1. Cancer Diagnostics Market, by Technology, 2022-2030

9.1.1. IVD Testing (PCR, ISH, IHC, NGS, Microarrays, Flow Cytometry, Immunoassays)

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Imaging (MRI, CT, PET, Mammography, Ultrasound)

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Biopsy Technique

9.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Cancer Diagnostics Market, By Application 

10.1. Cancer Diagnostics Market, by Application, 2022-2030

10.1.1. Breast Cancer

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Colorectal Cancer

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Cervical Cancer

10.1.3.1. Market Revenue and Forecast (2019-2030)

10.1.4. Lung Cancer

10.1.4.1. Market Revenue and Forecast (2019-2030)

10.1.5. Prostate Cancer

10.1.5.1. Market Revenue and Forecast (2019-2030)

10.1.6. Skin Cancer

10.1.6.1. Market Revenue and Forecast (2019-2030)

10.1.7. Blood Cancer

10.1.7.1. Market Revenue and Forecast (2019-2030)

10.1.8. Kidney Cancer

10.1.8.1. Market Revenue and Forecast (2019-2030)

10.1.9. Liver Cancer

10.1.9.1. Market Revenue and Forecast (2019-2030)

10.1.10. Pancreatic Cancer

10.1.10.1. Market Revenue and Forecast (2019-2030)

10.1.11. Ovarian Cancer

10.1.11.1. Market Revenue and Forecast (2019-2030)

10.1.12. Others

10.1.12.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Cancer Diagnostics Market, By End Use 

11.1. Cancer Diagnostics Market, by End Use, 2022-2030

11.1.1. Hospitals and Clinics

11.1.1.1. Market Revenue and Forecast (2019-2030)

11.1.2. Diagnostic Laboratories

11.1.2.1. Market Revenue and Forecast (2019-2030)

11.1.3. Diagnostic Imaging Centers

11.1.3.1. Market Revenue and Forecast (2019-2030)

11.1.4. Research Institutes

11.1.4.1. Market Revenue and Forecast (2019-2030)

Chapter 12. Global Cancer Diagnostics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2019-2030)

12.1.2. Market Revenue and Forecast, by Technology (2019-2030)

12.1.3. Market Revenue and Forecast, by Application (2019-2030)

12.1.4. Market Revenue and Forecast, by End Use (2019-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.1.5.2. Market Revenue and Forecast, by Technology (2019-2030)

12.1.5.3. Market Revenue and Forecast, by Application (2019-2030)

12.1.5.4. Market Revenue and Forecast, by End Use (2019-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.1.6.2. Market Revenue and Forecast, by Technology (2019-2030)

12.1.6.3. Market Revenue and Forecast, by Application (2019-2030)

12.1.6.4. Market Revenue and Forecast, by End Use (2019-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.2. Market Revenue and Forecast, by Technology (2019-2030)

12.2.3. Market Revenue and Forecast, by Application (2019-2030)

12.2.4. Market Revenue and Forecast, by End Use (2019-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.5.2. Market Revenue and Forecast, by Technology (2019-2030)

12.2.5.3. Market Revenue and Forecast, by Application (2019-2030)

12.2.5.4. Market Revenue and Forecast, by End Use (2019-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.6.2. Market Revenue and Forecast, by Technology (2019-2030)

12.2.6.3. Market Revenue and Forecast, by Application (2019-2030)

12.2.6.4. Market Revenue and Forecast, by End Use (2019-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.7.2. Market Revenue and Forecast, by Technology (2019-2030)

12.2.7.3. Market Revenue and Forecast, by Application (2019-2030)

12.2.7.4. Market Revenue and Forecast, by End Use (2019-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.8.2. Market Revenue and Forecast, by Technology (2019-2030)

12.2.8.3. Market Revenue and Forecast, by Application (2019-2030)

12.2.8.4. Market Revenue and Forecast, by End Use (2019-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.2. Market Revenue and Forecast, by Technology (2019-2030)

12.3.3. Market Revenue and Forecast, by Application (2019-2030)

12.3.4. Market Revenue and Forecast, by End Use (2019-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.5.2. Market Revenue and Forecast, by Technology (2019-2030)

12.3.5.3. Market Revenue and Forecast, by Application (2019-2030)

12.3.5.4. Market Revenue and Forecast, by End Use (2019-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.6.2. Market Revenue and Forecast, by Technology (2019-2030)

12.3.6.3. Market Revenue and Forecast, by Application (2019-2030)

12.3.6.4. Market Revenue and Forecast, by End Use (2019-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.7.2. Market Revenue and Forecast, by Technology (2019-2030)

12.3.7.3. Market Revenue and Forecast, by Application (2019-2030)

12.3.7.4. Market Revenue and Forecast, by End Use (2019-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.8.2. Market Revenue and Forecast, by Technology (2019-2030)

12.3.8.3. Market Revenue and Forecast, by Application (2019-2030)

12.3.8.4. Market Revenue and Forecast, by End Use (2019-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.2. Market Revenue and Forecast, by Technology (2019-2030)

12.4.3. Market Revenue and Forecast, by Application (2019-2030)

12.4.4. Market Revenue and Forecast, by End Use (2019-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.5.2. Market Revenue and Forecast, by Technology (2019-2030)

12.4.5.3. Market Revenue and Forecast, by Application (2019-2030)

12.4.5.4. Market Revenue and Forecast, by End Use (2019-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.6.2. Market Revenue and Forecast, by Technology (2019-2030)

12.4.6.3. Market Revenue and Forecast, by Application (2019-2030)

12.4.6.4. Market Revenue and Forecast, by End Use (2019-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.7.2. Market Revenue and Forecast, by Technology (2019-2030)

12.4.7.3. Market Revenue and Forecast, by Application (2019-2030)

12.4.7.4. Market Revenue and Forecast, by End Use (2019-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.8.2. Market Revenue and Forecast, by Technology (2019-2030)

12.4.8.3. Market Revenue and Forecast, by Application (2019-2030)

12.4.8.4. Market Revenue and Forecast, by End Use (2019-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.5.2. Market Revenue and Forecast, by Technology (2019-2030)

12.5.3. Market Revenue and Forecast, by Application (2019-2030)

12.5.4. Market Revenue and Forecast, by End Use (2019-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.5.5.2. Market Revenue and Forecast, by Technology (2019-2030)

12.5.5.3. Market Revenue and Forecast, by Application (2019-2030)

12.5.5.4. Market Revenue and Forecast, by End Use (2019-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.5.6.2. Market Revenue and Forecast, by Technology (2019-2030)

12.5.6.3. Market Revenue and Forecast, by Application (2019-2030)

12.5.6.4. Market Revenue and Forecast, by End Use (2019-2030)

Chapter 13. Company Profiles

13.1. Agilent Technologies, Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Thermo Fisher Scientific, Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Illumina, Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Becton, Dickinson and Company

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GE Healthcare

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. QIAGEN N.V.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Abbott Laboratories, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Roche Diagnostics

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Siemens Healthcare

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Philips Healthcare

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

13.11. R. Bard, Inc.

13.11.1. Company Overview

13.11.2. Product Offerings

13.11.3. Financial Performance

13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Show More

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Related Articles

Check Also
Close
Back to top button